[go: up one dir, main page]

NO932212L - POLYAMINMEDIKAMENT-RESIN COMPLEXES - Google Patents

POLYAMINMEDIKAMENT-RESIN COMPLEXES

Info

Publication number
NO932212L
NO932212L NO93932212A NO932212A NO932212L NO 932212 L NO932212 L NO 932212L NO 93932212 A NO93932212 A NO 93932212A NO 932212 A NO932212 A NO 932212A NO 932212 L NO932212 L NO 932212L
Authority
NO
Norway
Prior art keywords
drug
cation exchange
resin
polyaminmedikament
resin complex
Prior art date
Application number
NO93932212A
Other languages
Norwegian (no)
Other versions
NO932212D0 (en
Inventor
William Joseph Kelleher
Anthony Earl Carpanzano
Original Assignee
Richardson Vicks Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richardson Vicks Inc filed Critical Richardson Vicks Inc
Publication of NO932212D0 publication Critical patent/NO932212D0/en
Publication of NO932212L publication Critical patent/NO932212L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Det er angitt orale farmasøytiske preparater som omfatter et farmakologisk aktivt polyamin-medikament bundet til en kation- bytter-harpiks for å tilveiebringe et medikament-harpikskompleks med et medikament-innhold større enn en amin-ekviva- lent per ekvivalent kationbytter-kapasitet. Medikament- harpikskomplekset er eventuelt dekket med et vannpermeabelt diffusjonsbarriere-overtrekk som er uoppløselig i mage- og tarm-fluider, og tilveiebringer derved en kontrollerbar medikamentfrigivelse under de forhold som påtreffes i mage- og tarm-systemet.Oral pharmaceutical compositions are disclosed which comprise a pharmacologically active polyamine drug bound to a cation exchange resin to provide a drug-resin complex having a drug content greater than one amine equivalent per equivalent cation exchange capacity. The drug-resin complex is optionally covered with a water-permeable diffusion barrier coating which is insoluble in gastrointestinal fluids, thereby providing a controllable drug release under the conditions encountered in the gastrointestinal system.

NO93932212A 1990-12-21 1993-06-16 POLYAMINMEDIKAMENT-RESIN COMPLEXES NO932212L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63229090A 1990-12-21 1990-12-21
PCT/US1991/009463 WO1992011038A1 (en) 1990-12-21 1991-12-16 Polyamine drug-resin complexes

Publications (2)

Publication Number Publication Date
NO932212D0 NO932212D0 (en) 1993-06-16
NO932212L true NO932212L (en) 1993-08-20

Family

ID=24534913

Family Applications (1)

Application Number Title Priority Date Filing Date
NO93932212A NO932212L (en) 1990-12-21 1993-06-16 POLYAMINMEDIKAMENT-RESIN COMPLEXES

Country Status (17)

Country Link
EP (1) EP0563294A1 (en)
JP (1) JPH06504059A (en)
CN (1) CN1063221A (en)
AU (1) AU663695B2 (en)
BR (1) BR9107173A (en)
CA (1) CA2098200A1 (en)
CZ (1) CZ119793A3 (en)
FI (1) FI932842A7 (en)
HU (1) HUT74642A (en)
IE (1) IE914513A1 (en)
MX (1) MX9102753A (en)
MY (1) MY107811A (en)
NO (1) NO932212L (en)
NZ (1) NZ241097A (en)
PT (1) PT99912A (en)
SK (1) SK59493A3 (en)
WO (1) WO1992011038A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0664699A1 (en) * 1993-08-13 1995-08-02 Vitaphore Corporation Hydrogel-based microsphere drug delivery systems
DE69432867T2 (en) * 1993-11-18 2004-04-22 Sirtex Medical Ltd., Burswood PREPARATION WITH CONTROLLED RELEASE
ES2097087B1 (en) * 1994-08-01 1997-12-16 Univ Sevilla CONTROLLED RELEASE SYSTEM FOR MORPHINE AND OTHER PHARMACLES SOLUBLE IN WATER BY COMPLEXING WITH POLYMERIC SUBSTANCES.
WO1998027961A2 (en) * 1996-12-20 1998-07-02 Warner Lambert Company Antitussive drugs delivered by partially coated ion exchange resins
UA73092C2 (en) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Tablets with enteric coating and method for their manufacture
KR20020016069A (en) * 2000-08-24 2002-03-04 민경윤 An oral composition of a macrolide antibiotic and a process for preparing same
MXPA06002300A (en) 2003-09-03 2006-05-19 Mallinckrodt Inc Granular sustained release preparation and production thereof.
CN100415297C (en) * 2006-08-28 2008-09-03 浙江大学 Preparation method of zinc supplement based on cation exchange resin
CN100411629C (en) * 2006-08-28 2008-08-20 浙江大学 A kind of preparation method of sustained-release iron supplement
EP2500016A1 (en) 2011-03-18 2012-09-19 Laboratorios Del. Dr. Esteve, S.A. Doxylamine resinate complex
WO2015076821A1 (en) * 2013-11-22 2015-05-28 Tris Pharma, Inc. Novel clonidine formulation
US11918689B1 (en) 2020-07-28 2024-03-05 Tris Pharma Inc Liquid clonidine extended release composition
WO2025165367A1 (en) * 2024-02-02 2025-08-07 Tris Pharma, Inc. Liquid clonidine extended release composition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4221778A (en) * 1979-01-08 1980-09-09 Pennwalt Corporation Prolonged release pharmaceutical preparations
CA1236023A (en) * 1984-07-18 1988-05-03 Yegnaswami Raghunathan Controlled release pharmaceutical preparations
US4894239A (en) * 1987-06-02 1990-01-16 Takeda Chemical Industries, Ltd. Sustained-release preparation and production thereof
IL90245A (en) * 1988-05-11 1994-04-12 Glaxo Group Ltd Resin adsorbate comprising ranitidine together with a synthetic cation exchange resin, its preparation and pharmaceutical compositions containing it
FR2634377B1 (en) * 1988-06-30 1991-09-27 Cortial NOVEL EXTENDED RELEASE PHARMACEUTICAL FORM BASED ON AN ACTIVE RESIN-PRINCIPLE COMPLEX
US4996047A (en) * 1988-11-02 1991-02-26 Richardson-Vicks, Inc. Sustained release drug-resin complexes

Also Published As

Publication number Publication date
CN1063221A (en) 1992-08-05
AU663695B2 (en) 1995-10-19
IE914513A1 (en) 1992-07-01
WO1992011038A1 (en) 1992-07-09
MX9102753A (en) 1992-06-30
FI932842L (en) 1993-06-18
CZ119793A3 (en) 1994-01-19
JPH06504059A (en) 1994-05-12
HU9301819D0 (en) 1993-09-28
FI932842A0 (en) 1993-06-18
AU9168791A (en) 1992-07-22
EP0563294A1 (en) 1993-10-06
SK59493A3 (en) 1993-11-10
FI932842A7 (en) 1993-06-18
CA2098200A1 (en) 1992-06-21
HUT74642A (en) 1997-01-28
NO932212D0 (en) 1993-06-16
NZ241097A (en) 1994-11-25
PT99912A (en) 1993-01-29
BR9107173A (en) 1993-11-16
MY107811A (en) 1996-06-29

Similar Documents

Publication Publication Date Title
NO932212L (en) POLYAMINMEDIKAMENT-RESIN COMPLEXES
DK546389D0 (en) PHARMACEUTICAL COMPOSITION ON UNIT DOSAGE FORM FOR PERORAL ADMINISTRATION
FR2678169B1 (en) NOVEL PHARMACEUTICAL COMPOSITIONS COMPRISING A CYCLOSPORIN, FOR ORAL ADMINISTRATION.
DK0740650T3 (en) Codrugs as a method of controlled drug transport
ATE312602T1 (en) EXTENDED-RELEASE ORAL PHARMACEUTICAL DOSAGE FORM
DZ1876A1 (en) Medicines for oral administration.
FR2698787B1 (en) Medicinal patches for percutaneous administration.
DE59100067D1 (en) PIMOBENDAN ORAL MEDICINE FORMS.
DE60005819D1 (en) TASTE-MASKED ORAL PHARMACEUTICAL COMPOSITIONS WITH CONTROLLED DELIVERY
IL135148A0 (en) A polysaccharide conjugate and pharmaceutical compositions containing the same
PT789708E (en) MULTIFUNCTIONAL MOLECULAR COMPLEXES FOR TRANSFER OF GENES FOR CELLS
TR200003108T2 (en) Pharmaceutical compositions
ATE216246T1 (en) PHARMACEUTICAL PREPARATION BASED ON A DICLOFENAC SALT AND THE COMPOUND THIOCOLCHICOSIDE
NO911344L (en) PHARMACEUTICAL PREPARATION WITH NITROGLYSERINE FOR PERCUTANEOUS ADMINISTRATION.
ATE321538T1 (en) ORAL PHARMACEUTICAL FORM FOR PYRIDINE-2-YLMETHYLSULFINYL-1H-BENZIMIDAZOLE
NO990282L (en) Absorbsjonsforsterker
NO20015480L (en) Microgranules that are not soluble in gastric juice, methods for achieving the same and pharmaceutical preparations
CA2066031A1 (en) Methods for reducing non-target retention of immunoconjugates and metabolites thereof
RU97112236A (en) METHOD FOR TREATING MALIGNANT BONE TUMORS AND METASTASES IN OSTEOLITICAL CHARACTER BONE
DK0742716T3 (en) Pharmaceutical composition for systemic transdermal administration with the morphine-6-glucuronide active agent
ITRM920535A1 (en) PHARMACEUTICAL COMPOSITION FOR ADMINISTRATION THROUGH THE MUCOSES.
DE59501945D1 (en) Oral drug preparation containing diclofenac sodium and an organic acid
IT1244373B (en) PHARMACEUTICAL COMPOSITIONS FOR ORAL USE CONTAINING LOW MOLECULAR WEIGHT HEPARIN, THEIR PREPARATION AND USE
CA2190867A1 (en) Methods for reduced renal uptake of antibody fragments
RU98103035A (en) METHOD FOR PREPARING PATIENTS FOR CORONAROGRAPHY